These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37373436)

  • 1. Denosumab Attenuates Glucolipotoxicity-Induced β-Cell Dysfunction and Apoptosis by Attenuating RANK/RANKL Signals.
    Lin SC; Tsou SH; Kuo CY; Chen WL; Wu KW; Lin CL; Huang CN
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL/RANK is required for cytokine-induced beta cell death; osteoprotegerin, a RANKL inhibitor, reverses rodent type 1 diabetes.
    Kondegowda NG; Filipowska J; Do JS; Leon-Rivera N; Li R; Hampton R; Ogyaadu S; Levister C; Penninger JM; Reijonen H; Levy CJ; Vasavada RC
    Sci Adv; 2023 Nov; 9(44):eadf5238. PubMed ID: 37910614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway.
    Kondegowda NG; Fenutria R; Pollack IR; Orthofer M; Garcia-Ocaña A; Penninger JM; Vasavada RC
    Cell Metab; 2015 Jul; 22(1):77-85. PubMed ID: 26094891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liraglutide protects against glucolipotoxicity-induced RIN-m5F β-cell apoptosis through restoration of PDX1 expression.
    Kornelius E; Li HH; Peng CH; Yang YS; Chen WJ; Chang YZ; Bai YC; Liu S; Huang CN; Lin CL
    J Cell Mol Med; 2019 Jan; 23(1):619-629. PubMed ID: 30353648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent Insights Into Mechanisms of β-Cell Lipo- and Glucolipotoxicity in Type 2 Diabetes.
    Lytrivi M; Castell AL; Poitout V; Cnop M
    J Mol Biol; 2020 Mar; 432(5):1514-1534. PubMed ID: 31628942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
    Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
    J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin/Receptor Activator of Nuclear Factor-Kappa B Ligand/Receptor Activator of Nuclear Factor-Kappa B Axis in Obesity, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease.
    Vachliotis ID; Polyzos SA
    Curr Obes Rep; 2023 Jun; 12(2):147-162. PubMed ID: 37208545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the RANKL/RANK/OPG system.
    Yasuda H
    J Bone Miner Metab; 2021 Jan; 39(1):2-11. PubMed ID: 33389131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
    Bayer CM; Beckmann MW; Fasching PA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.
    Lacey DL; Boyle WJ; Simonet WS; Kostenuik PJ; Dougall WC; Sullivan JK; San Martin J; Dansey R
    Nat Rev Drug Discov; 2012 May; 11(5):401-19. PubMed ID: 22543469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass.
    Bonnet N; Bourgoin L; Biver E; Douni E; Ferrari S
    J Clin Invest; 2019 May; 129(8):3214-3223. PubMed ID: 31120440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
    de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
    J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
    Chen T; Feng X
    Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways.
    Vitovski S; Phillips JS; Sayers J; Croucher PI
    J Biol Chem; 2007 Oct; 282(43):31601-9. PubMed ID: 17702740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. microRNA-143-3p regulates odontogenic differentiation of human dental pulp stem cells through regulation of the osteoprotegerin-RANK ligand pathway by targeting RANK.
    Yang C; Jia R; Zuo Q; Zheng Y; Wu Q; Luo B; Lin P; Yin L
    Exp Physiol; 2020 May; 105(5):876-885. PubMed ID: 32052500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.
    Schieferdecker A; Voigt M; Riecken K; Braig F; Schinke T; Loges S; Bokemeyer C; Fehse B; Binder M
    Oncotarget; 2014 Aug; 5(16):6647-53. PubMed ID: 25138051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of recent spinal cord injury on the OPG/RANKL system and its relationship with bone loss and the response to denosumab therapy.
    Gifre L; Ruiz-Gaspà S; Carrasco JL; Portell E; Vidal J; Muxi A; Monegal A; Guañabens N; Peris P
    Osteoporos Int; 2017 Sep; 28(9):2707-2715. PubMed ID: 28580511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications.
    Greco T; Mascio A; Comisi C; Polichetti C; Caravelli S; Mosca M; Mondanelli N; Troiano E; Maccauro G; Perisano C
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirtuin 5 overexpression attenuates glucolipotoxicity-induced pancreatic β cells apoptosis and dysfunction.
    Wang Y; Liu Q; Huan Y; Li R; Li C; Sun S; Guo N; Yang M; Liu S; Shen Z
    Exp Cell Res; 2018 Oct; 371(1):205-213. PubMed ID: 30098330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
    Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
    Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.